CN104736550B - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN104736550B
CN104736550B CN201380050112.1A CN201380050112A CN104736550B CN 104736550 B CN104736550 B CN 104736550B CN 201380050112 A CN201380050112 A CN 201380050112A CN 104736550 B CN104736550 B CN 104736550B
Authority
CN
China
Prior art keywords
compound
group
formula
stereochemistry
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380050112.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104736550A (zh
Inventor
本杰明·杰森·康普顿
柯林·马尔科姆·海曼
伊恩·弗朗西斯·赫曼斯
大卫·塞缪尔·拉森
加文·弗兰克·佩特
里根·詹姆斯·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victoria Link Ltd
Original Assignee
Victoria Link Ltd
Callaghan Innovation Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria Link Ltd, Callaghan Innovation Research Ltd filed Critical Victoria Link Ltd
Publication of CN104736550A publication Critical patent/CN104736550A/zh
Application granted granted Critical
Publication of CN104736550B publication Critical patent/CN104736550B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380050112.1A 2012-07-26 2013-07-26 有机化合物 Expired - Fee Related CN104736550B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ60147312 2012-07-26
NZ601473 2012-07-26
PCT/NZ2013/000133 WO2014017928A1 (en) 2012-07-26 2013-07-26 Organic compounds

Publications (2)

Publication Number Publication Date
CN104736550A CN104736550A (zh) 2015-06-24
CN104736550B true CN104736550B (zh) 2017-12-29

Family

ID=49997620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380050112.1A Expired - Fee Related CN104736550B (zh) 2012-07-26 2013-07-26 有机化合物

Country Status (9)

Country Link
US (1) US9586985B2 (cg-RX-API-DMAC7.html)
EP (1) EP2877481B1 (cg-RX-API-DMAC7.html)
JP (1) JP6528029B2 (cg-RX-API-DMAC7.html)
KR (1) KR102162619B1 (cg-RX-API-DMAC7.html)
CN (1) CN104736550B (cg-RX-API-DMAC7.html)
AU (1) AU2013293646B2 (cg-RX-API-DMAC7.html)
CA (1) CA2880191C (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00492A (cg-RX-API-DMAC7.html)
WO (1) WO2014017928A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6548579B2 (ja) * 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9717790B2 (en) * 2013-06-10 2017-08-01 Victoria Link Limited Sphingoglycolipid analogues
US10046046B2 (en) 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
JP6453033B2 (ja) * 2014-10-22 2019-01-16 国立大学法人北海道大学 糖スフィンゴシン及びスフィンゴ塩基の製造方法
US9394312B1 (en) * 2015-06-14 2016-07-19 Mark Quang Nguyen Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use
EP3374028B1 (en) * 2015-11-13 2021-05-26 La Jolla Institute for Allergy and Immunology Sphingamide compounds and methods for binding inkt cells
EP3434684A4 (en) * 2016-03-22 2019-11-27 Keio University COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR AND PHARMACEUTICAL COMPOSITION
WO2019122050A1 (en) 2017-12-22 2019-06-27 Isa Pharmaceuticals B.V. Methods of immunization
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
WO2007035717A2 (en) * 2005-09-19 2007-03-29 The Rockefeller University Glycolipids and analogues thereof as antigents for nk t cells
CN101010086A (zh) * 2004-08-27 2007-08-01 耶希瓦大学艾伯塔·爱恩斯坦医学院 作为免疫和自身免疫调节剂的神经酰胺衍生物
WO2008128062A1 (en) * 2007-04-13 2008-10-23 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
JP3824319B2 (ja) 2004-02-19 2006-09-20 株式会社紀文フードケミファ 抗ウイルス作用組成物
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Nkt細胞に対する抗原としての糖脂質及びその類似体
WO2008047174A1 (en) * 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
US20080133801A1 (en) * 2006-12-04 2008-06-05 Aten International Co., Ltd. Keyboard-video-mouse switch system for switching between computers having a plurality of video sources each and switching method thereof
US7731851B2 (en) 2007-04-12 2010-06-08 Novozymes Biologicals, Inc. Waste water treatment
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
US9220767B2 (en) * 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024691A1 (en) * 2004-03-25 2006-02-02 Buck Institute For Age Research Novel pathways in the etiology of cancer
CN101010086A (zh) * 2004-08-27 2007-08-01 耶希瓦大学艾伯塔·爱恩斯坦医学院 作为免疫和自身免疫调节剂的神经酰胺衍生物
WO2007035717A2 (en) * 2005-09-19 2007-03-29 The Rockefeller University Glycolipids and analogues thereof as antigents for nk t cells
WO2008128062A1 (en) * 2007-04-13 2008-10-23 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells

Also Published As

Publication number Publication date
JP2015522656A (ja) 2015-08-06
US9586985B2 (en) 2017-03-07
CA2880191C (en) 2021-04-20
KR20150073942A (ko) 2015-07-01
WO2014017928A1 (en) 2014-01-30
CA2880191A1 (en) 2014-01-30
EP2877481A4 (en) 2016-04-06
AU2013293646A1 (en) 2015-03-12
US20150191503A1 (en) 2015-07-09
EP2877481A1 (en) 2015-06-03
KR102162619B1 (ko) 2020-10-08
IN2015KN00492A (cg-RX-API-DMAC7.html) 2015-07-17
AU2013293646B2 (en) 2017-10-19
CN104736550A (zh) 2015-06-24
JP6528029B2 (ja) 2019-06-12
EP2877481B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
CN105008380B (zh) 缀合化合物
CN104736550A (zh) 有机化合物
ES2654382T3 (es) Método para la preparación de glucoesfingolípidos
CA2577009C (en) Ceramide derivatives as modulators of immunity and autoimmunity
US6555372B1 (en) Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
TWI768365B (zh) 皂苷共軛物及含其之疫苗或藥物組合物
JP5669215B2 (ja) 新規合成糖脂質およびその用途
US10046046B2 (en) Amino sphingoglycolipid analogues
US9717790B2 (en) Sphingoglycolipid analogues
NZ613614B2 (en) Sphingoglycolipid compounds and uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20171020

Address after: Wellington

Applicant after: VICTORIA LINK Ltd.

Address before: New Zealand under Hart

Applicant before: Callaghan Innovation

Applicant before: The outstanding gloomy Compton of Benjamin

Applicant before: Ke Lin Malcolm Heyman

Applicant before: Her grace Mark Lewis-Francis Theo Hermans

Applicant before: David Sai Miaoer Larsen

Applicant before: Add civilian Frank Pei Te

Applicant before: Rigen James Anderson

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171229

CF01 Termination of patent right due to non-payment of annual fee